Abstract
Objective To compare the effects of consuming food-based versus supplement-based very low-energy diet (VLED) programs on gut microbiome composition in women with a high body mass index (BMI).
Design An investigator-initiated, single-blind, two-arm, parallel-group randomised controlled-feeding trial with computer-generated 1:1 randomisation. From May 2021 to February 2022, women aged 30– 65 years with BMI 30–45 kg/m2 were recruited from southwest Victoria, Australia, and randomised to a three-week food-based or supplement-based VLED program. The primary outcome was between-group differential change in faecal microbiome alpha diversity (Shannon index) from baseline to week three, assessed using shotgun metagenomics. Outcome assessors, study investigators, and analysing statisticians were blinded to group allocation until analysis completion. Allocation concealment was managed by an independent researcher using a computer software system. Modified intention-to-treat (mITT) analyses using linear mixed-effects regression models estimated mean between-group differential changes, reported as beta-coefficient point estimates (β) and 95% confidence intervals (95%CI), adjusted for multiple comparisons.
Results Forty-seven participants were randomised (food-based: n=23, supplement-based: n=24). Of the 45 participants analysed, there was a between-group differential change in the Shannon index (mITT β: 0.37, 95%CI: 0.15 to 0.60) from baseline to week three, with a greater increase in the food-based group (mean change: 0.26, 95%CI: 0.09 to 0.44; n=23) versus supplement-based group (mean change: −0.10, 95%CI: −0.25 to 0.05; n=22). There were 27 non-serious adverse events (food-based: 8, supplement-based: 19), all non-serious.
Conclusion A food-based VLED, with more whole food components and fewer highly processed industrial ingredients, increases gut microbiome diversity more than a supplement-based VLED.
Summary Box What is already known on this topic
Dietary interventions can alter gut microbiome composition, but the impact of food processing, including in nutritionally balanced very low energy diets (VLEDs), is less understood.
What this study adds
This study shows that a food-based VLED, with more whole food components and fewer highly processed industrial ingredients, increases gut microbiome diversity more than a supplement-based VLED.
How this study might affect research, practice, or policy. Summarise the implications of this study
Our findings underscore the need for further research into how specific components and attributes of diets, both including and beyond nutritional composition, influence the gut microbiome.
Competing Interest Statement
MML is Secretary for the Melbourne Branch Committee of the Nutrition Society of Australia (unpaid) and has received travel funding support from the International Society for Nutritional Psychiatry Research, the Nutrition Society of Australia, the Australasian Society of Lifestyle Medicine, and the Gut Brain Congress. AJM is immediate past Secretary for the International Society for Nutritional Psychiatry Research (unpaid) and is funded through the NHMRC supported CREDIT CRE, the Centre for Research Excellence for the Development of Innovative Therapies. MB is supported by a NHMRC Senior Principal Research Fellowship (1156072). MB has received Grant/Research Support from the NIH, Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, Medical Benefits Fund, National Health and Medical Research Council, Medical Research Futures Fund, Beyond Blue, Rotary Health, A2 milk company, Meat and Livestock Board, Woolworths, Avant and the Harry Windsor Foundation, has been a speaker for Abbot, Astra Zeneca, Janssen and Janssen, Lundbeck and Merck and served as a consultant to Allergan, Astra Zeneca, Bioadvantex, Bionomics, Collaborative Medicinal Development, Janssen and Janssen, Lundbeck Merck, Pfizer and Servier - all unrelated to this work. AL has received grant, research or travel support from Deakin University, The University of Melbourne, RMIT University, National Health and Medical Research Council, Australian Academy of Science, The Jack Brockhoff Foundation, Epilepsy Foundation of Australia, American Epilepsy Society and has received speakers' honoraria from European Space Agency, Swisse Australia - all unrelated to this work. AL is a named inventor on a patent relating to Prevotella. MM has received Grant/research support from the NHMRC, Deakin University School of Medicine, Deakin Biostatistics Unit, Institute for Mental and Physical Health and Clinical Translation, Stroke Foundation and Medibank Health Research Fund. WM is currently funded by an NHMRC Investigator Grant (#2008971). WM has previously received funding from the Cancer Council Queensland and university grants/fellowships from La Trobe University, Deakin University, University of Queensland, and Bond University. WM has received funding and/or has attended events funded by Cobram Estate Pty. Ltd and Bega Dairy and Drinks Pty Ltd. WM has received travel funding from Nutrition Society of Australia. WM has received consultancy funding from Nutrition Research Australia and ParachuteBH. WM has received speakers honoraria from VitaFoods, The Cancer Council Queensland and the Princess Alexandra Research Foundation. FNJ has received: competitive Grant/Research support from the Brain and Behaviour Research Institute, the National Health and Medical Research Council (NHMRC), Australian Rotary Health, the Geelong Medical Research Foundation, the Ian Potter Foundation, The University of Melbourne; industry support for research from Meat and Livestock Australia, Woolworths Limited, the A2 Milk Company, Be Fit Food; philanthropic support from the Fernwood Foundation, Wilson Foundation, the JTM Foundation, the Serp Hills Foundation, the Roberts Family Foundation, the Waterloo Foundation and; travel support and speakers honoraria from Sanofi-Synthelabo, Janssen Cilag, Servier, Pfizer, Network Nutrition, Angelini Farmaceutica, Eli Lilly and Metagenics. FNJ has written two books for commercial publication. She is on the Scientific Advisory Board of the Dauten Family Centre for Bipolar Treatment Innovation and Zoe Limited. She is currently supported by an NHMRC Investigator Grant L1 (#1194982). The Food & Mood Centre has received Grant/Research support from the a2 Milk Company, Be Fit Food, Meat and Livestock Australia, and Woolworths Limited, and philanthropic support from the Fernwood Foundation, Wilson Foundation, the JTM Foundation, the Serp Hills Foundation, the Roberts Family Foundation, and the Waterloo Foundation. AO receives funding support from the National Health and Medical Research Council (#2009295).
Clinical Trial
ACTRN12620000301965
Funding Statement
Aspects of this study (biochemical analyses) were funded by Be Fit Food. Investigational products were provided by Be Fit Food as in-kind support. The study was supported and sponsored by Deakin University. Both the study funders and sponsors were independent of the study design and oversight, had no role in study design, in the collection, analysis, and interpretation of data, in the writing of the report, and/or in the decision to submit the paper for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This trial received ethical approval from the Barwon Health (19/112) and Deakin University (2018/211) Human Research Ethics Committees.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
To access additional data from this study, the code and raw data can be found on GitHub and NCBI Sequence Read Archive, respectively. For further assistance or inquiries, please contact the corresponding author.
